Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
0.781
+0.010 (1.31%)
At close: Dec 20, 2024, 4:00 PM
0.795
+0.014 (1.79%)
After-hours: Dec 20, 2024, 5:30 PM EST
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $1.17M in the quarter ending September 30, 2024, with 49.68% growth. This brings the company's revenue in the last twelve months to $4.19M, up 179.27% year-over-year. In the year 2023, Lucid Diagnostics had annual revenue of $2.43M with 544.03% growth.
Revenue (ttm)
$4.19M
Revenue Growth
+179.27%
P/S Ratio
8.67
Revenue / Employee
$59,843
Employees
70
Market Cap
43.30M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DIH Holding US | 73.49M |
Rapid Micro Biosystems | 26.17M |
Omega Therapeutics | 8.10M |
CollPlant Biotechnologies | 650.00K |
Cardio Diagnostics Holdings | 35.69K |
LUCD News
- 2 days ago - Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - PRNewsWire
- 10 days ago - Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PRNewsWire
- 18 days ago - Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PRNewsWire
- 4 weeks ago - Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 5 weeks ago - Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PRNewsWire
- 6 weeks ago - Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PRNewsWire